Research
Hormonal
Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.
Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.
StrongSupportsmedium confidence
Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.
Why this rating
Supported by randomized clinical trials and real-world studies.
Source
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey et al. · Peptides · 2025
reviewCited 20×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →